Pembrolizumab

The development of the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab and its approval in 2011 for the treatment of metastatic melanoma has heralded a new era in immuno-oncology. Subsequently, novel agents against the programmed death receptor 1 (PD-1)/programmed death receptor lig...

Descripción completa

Detalles Bibliográficos
Autores principales: Khoja, Leila, Butler, Marcus O., Kang, S. Peter, Ebbinghaus, Scot, Joshua, Anthony M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539882/
https://www.ncbi.nlm.nih.gov/pubmed/26288737
http://dx.doi.org/10.1186/s40425-015-0078-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539882/
https://www.ncbi.nlm.nih.gov/pubmed/26288737
http://dx.doi.org/10.1186/s40425-015-0078-9

Ejemplares similares